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The aim of the study is to determine the role of lymphadenectomy in advanced epithelial ovarian cancer. The data were obtained
from the Surveillance, Epidemiology and End Results (SEER) program reported between 1988 and 2001. Kaplan–Meier estimates
and Cox proportional hazards regression models were used for analysis. Of 13918 women with stage III–IV epithelial ovarian cancer
(median age: 64 years), 87.9% were Caucasian, 5.6% African Americans, and 4.4% Asians. A total of 4260 (30.6%) underwent lymph
node dissections with a median number of six nodes reported. For all patients, a more extensive lymph node dissection (0, 1, 2–5,
6–10, 11–20, and 420 nodes) was associated with an improved 5-year disease-specific survival of 26.1, 35.2, 42.6, 48.4, 47.5, and
47.8%, respectively (Po0.001). Of the stage IIIC patients with nodal metastases, the extent of nodal resection (1, 2–5, 6–10, 11–20,
and 420 nodes) was associated with improved survivals of 36.9, 45.0, 47.8, 48.7, and 51.1%, respectively (P¼0.023). On multivariate
analysis, the extent of lymph node dissection and number of positive nodes were significant independent prognosticators after
adjusting for age, year at diagnosis, stage, and grade of disease. The extent of lymphadenectomy is associated with an improved
disease-specific survival of women with advanced epithelial ovarian cancer.
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Ovarian cancer is the most lethal gynaecologic malignancy, and is
the fifth-highest cause of cancer deaths in women in the United
States. In 2006, it was estimated that 20180 women will be
diagnosed with ovarian cancer, and 15310 will die of the disease
(Jemal et al, 2006). The standard of care in the treatment of
patients with advanced-stage epithelial ovarian cancer includes
primary cytoreduction surgery, followed by a platinum-based
chemotherapy regimen (Marsden et al, 2000; Bristow et al, 2002).
A major controversy in the surgical treatment of advanced-stage
ovarian cancer concerns the optimal management of the retro-
peritoneal lymph nodes. Approaches ranging from biopsy of only
grossly enlarged nodes to systematic dissection of bilateral pelvic
and paraaortic lymph nodes have been employed. Retroperitoneal
lymph node involvement is reported in 50–75% of patients with
advanced-stage disease at the time of primary surgery (Chen and
Lee, 1983; Burghardt et al, 1989, 1991; Onda et al, 1996). It is
unclear whether lymphadenectomy aids in better staging of
patients, or whether the procedure itself has therapeutic value by
debulking gross and occult disease. Prior retrospective reports
support the role of lymphadenectomy in ovarian epithelial cancer
(Burghardt et al, 1986; Scarabelli et al, 1995). However, others have
not found a benefit associated with systematic lymphadenectomy
(Spirtos et al, 1995).
Benedetti Panici et al (2005) reported the results of a prospective
trial on 427 patients with optimally debulked stage IIIB–IV
epithelial ovarian cancer randomised to systematic pelvic and
paraaortic lymphadenectomy vs resection of bulky nodes only.
Those who underwent a systematic lymph node dissection had a
7-month improvement in progression-free survival (29.4 vs 22.4
months). However, they were unable to demonstrate a significant
overall survival benefit.
Given that most of the prior retrospective studies have been
limited by a small sample size, we performed a large population-
based study to investigate the role of lymphadenectomy in patients
with advanced-stage ovarian cancers. Our study analysed the
disease-specific survival outcomes of 13918 patients diagnosed
with advanced-stage epithelial ovarian cancer to determine the
potential role of lymph node dissection.
MATERIALS AND METHODS
Demographic, clinicopathologic, surgical, and survival informa-
tion of women diagnosed with epithelial ovarian cancer during the
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speriod from 1 January 1988 to 31 December 2001 were extracted
with permission from the Surveillance, Epidemiology and End
Results (SEER) program of the United States National Cancer
Institute. This data represent approximately 14% of the US
population and are reported from 12 population-based registries
including San Francisco-Oakland, Connecticut, metropolitan
Detroit, Hawaii, Iowa, New Mexico, Seattle (Puget Sound), Utah,
metropolitan Atlanta, Alaska, San Jose-Monterey, and Los Angeles
(Hankey et al, 1999).
Only patients with advanced (stage III–IV) disease who had
undergone a surgical staging procedure were included in the
analysis. Patients with borderline tumours of the ovary, as well as
those patients with germ cell, sex cord stromal, and sarcoma
histologies, were excluded. Patients were assigned to the following
categories based on race classifications described by the SEER
program: Caucasian, African Americans, Asians, and others. Asians
were defined as Chinese, Japanese, Korean, Vietnamese, and
Filipino. All other race and ethnicity groups were defined as others.
In the assessment of demographic trends in the patient cohort,
and to determine 5-year disease-specific survival, w
2-tests and
Kaplan–Meier analyses with log-rank tests were performed. The
outcome of specific interest was death due to ovarian cancer
(disease-specific survival). The Cox proportional hazards model
was used to investigate the significance of extent of lymph node
resection (characterised by the number of lymph nodes reported)
after adjusting for other patient features, including age, race, year
of diagnosis, stage, and grade, and number of positive nodes. For
the analysis of the patients who had received a lymph node
dissection as part of their primary surgical treatment, the patients
were grouped based on the extent of the lymphadenectomy (1, 2–
5, 6–10, 11–20, and 420 nodes) to meet proportionality
assumptions. All data were analysed using Intercooled STATA
(version 8.0; STATA Corporation, College Station, TX, USA) and
SAS (version 6.12; SAS Inc., Cary, NC, USA).
RESULTS
Of the 13918 patients with stage III–IV epithelial ovarian cancer,
the median age was 62.7 years (range: 12–101). The median year of
diagnosis was 1995. The majority of patients were Caucasian
(87.9%), with African Americans, Asians, and others making up
5.6, 4.4, and 1.9% of patients, respectively (Table 1). After
undergoing surgical staging, 8062 patients had stage III disease
with 448 having stage IIIA, 672 stage IIIB, 4576 stage IIIC, and 5856
patients having stage IV ovarian cancer. Of the entire cohort, 4260
had a lymphadenectomy performed as part of their surgery, with a
median number of 6 nodes removed (range: 1–90). For patients
with positive nodes, the median number of positive nodes was two
(range: 1–54) and the median number of total nodes recovered
was seven (range: 1–90). In the study group, 66.8% of tumours
were of serous histology, 9.2% endometrioid, 5.6% mucinous, and
2.8% clear cell. A large proportion of patients had grade 3 disease
(60%), with 4.2 and 17.6% of patients having grade 1 and 2 disease,
respectively (Table 2). The median time of follow-up was 22
months (range: 0–167 months).
The 5-year disease-specific survival for those p64 years was
37.1 vs 24.4% for those 464 years (Po0.001). The survival of
patients with stage IIIA was 48.0%, IIIB 42.1%, and IIIC 36.7%.
Stage IV patients had a survival of 24.1% (Figure 1). Women with
grade 1, 2, and 3 tumours had survivals of 56.9, 33.4, and 29.2%,
respectively (Po0.001). The survival estimates based on histolo-
gies were serous 30.6%, endometrioid 43.6%, mucinous 33.3%, and
clear cell 25.5% (Po0.001).
To evaluate the effect of the extent of lymph node dissection, our
study cohort was divided into six groups: patients who had 0, 1, 2–
5, 6–10, 11–20, and 420 nodes reported. For all stages, we found
that the removal of increasing numbers of lymph nodes was
associated with a significant increase in 5-year disease-specific
survival (Table 3). The findings of 0, 1, 2–5, 6–10, 11–20, and
420 lymph nodes were associated with survivals of 26.1, 35.2, 42.6,
48.4, 47.5, and 47.8%, respectively (Po0.001; Figure 2 also). The
effect of extent of lymphadenectomy by histological subtype and
by grade is shown in Table 3. The 5-year disease-specific survival
rates were found to significantly increase when more nodes were
resected, within all grades and histologic types. In an analysis of
those patients (n¼2563) who were found to have nodal
metastases, the removal of a total of 1, 2–5, 6–10, 11–20, and
420 lymph nodes was associated with survival rates of 32.8, 36.8,
38.7, 42.0, and 41.7%, respectively (P¼0.002; Table 4). For 2188
Table 1 Patient characteristics
Total
(n¼13918)
No. (%)
a
0 nodes
(n¼9658)
No. (%)
a
1 node
(n¼824)
No. (%)
a
2–5 nodes
(n¼1202)
No. (%)
a
6–10 nodes
(n¼714)
No. (%)
a
11–20 nodes
(n¼813)
No. (%)
a
420 nodes
(n¼707)
No. (%)
a
Age at diagnosis (years)
Mean 62.7 (70.1) 64.1 (70.1) 60.9 (70.4) 59.9 (70.4) 59.1 (70.5) 58.1 (70.5) 57.1 (70.5)
Median (range) 64.0 (12–101) 65.0 (13–101) 61.0 (22–90) 60.0 (20–94) 59.5 (20–93) 58.0 (12–90) 57.0 (15–91)
Median year of
diagnosis
1995 1994 1995 1996 1997 1997 1998
Race
Caucasians 12240 (87.9%) 8498 (88.0%) 709 (86.0%) 1037 (86.3%) 629 (88.1%) 741 (91.1%) 626 (88.5%)
African
Americans
782 (5.6%) 549 (5.7%) 57 (6.9%) 83 (6.9%) 41 (5.7%) 32 (3.9%) 20 (2.8%)
Asians
b 612 (4.4%) 407 (4.2%) 36 (4.4%) 57 (4.7%) 30 (4.2%) 31 (3.8%) 51 (7.2%)
Others
c 267 (1.9%) 195 (2.0%) 22 (2.7%) 24 (2.0%) 12 (1.7%) 8 (1.0%) 6 (0.8%)
Unknown 17 (0.1%) 9 (0.1%) 0 (0.0%) 1 (0.1%) 2 (0.3%) 1 (0.1%) 4 (0.6%)
Year of diagnosis
1988–1992 4142 (29.8%) 3288 (34.0%) 265 (32.2%) 267 (22.2%) 129 (18.1%) 122 (15.0%) 71 (10.0%)
1993–1997 5327 (38.3%) 3766 (39.0%) 283 (34.3%) 489 (40.7%) 276 (38.7%) 296 (36.4%) 217 (30.7%)
1998–2001 4449 (31.9%) 2604 (27.0%) 276 (33.5%) 446 (37.1%) 309 (43.3%) 395 (48.6%) 419 (59.3%)
aPercentage of patients for given parameter.
bAsians were defined as Chinese, Japanese, Korean, Vietnamese, and Filipino.
cOthers were defined as all other race/ethnicity
parameters.
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spatients with stage IIIC disease and positive lymph nodes, survival
was noted to be significantly associated with a more extensive
lymphadenectomy. Additionally, the effect of the number of
positive nodes was investigated in subgroups of patients with IIIC-
IV node-positive disease, dividing patients into those with 1, 2–5,
and 45 positive lymph nodes. When 1, 2–5, and 45 positive
lymph nodes were found, the removal of increasing numbers of
negative lymph nodes was associated with improved survival
(Table 4).
On multivariate analysis, the extent of lymph node dissection,
both as a categorical and continuous variable, persisted as an
independent prognostic factor. In addition, age at diagnosis, stage,
grade, histologic cell type, number of positive nodes, and year of
diagnosis were also found to be significant prognosticators
(Table 5).
DISCUSSION
The standard therapy for advanced epithelial ovarian carcinoma
includes total hysterectomy, bilateral salpingo-oophorectomy,
omentectomy, washings, blind biopsies of diaphragm and
peritoneum, and optimal surgical cytoreduction, followed by
platinum-based chemotherapy. The prognostic value of complete
tumour debulking on the overall survival has been demonstrated
in many retrospective analyses (Piver et al, 1988; Covens, 2000;
Bristow et al, 2002). On the basis of a recent meta-analysis of 81
cohorts of patients with stage III–IV disease, it was found that for
each 10% increase in maximal cytoreduction, there was an
associated 5.5% increase in median survival (Bristow et al, 2002).
However, the role of retroperitoneal nodal resection remains
unclear, particularly for advanced-stage disease.
Table 2 Clinicopathologic data
Total
(n¼13918)
No. (%)
a
0 nodes
(n¼9658)
No. (%)
a
1 node
(n¼824)
No. (%)
a
2–5 nodes
(n¼1,202)
No. (%)
a
6–10 nodes
(n¼714)
No. (%)
a
11–20 nodes
(n¼813)
No. (%)
a
420 Nodes
(n¼707)
No. (%)
a
Chi-square
Test P-value
Stage of disease
Stage IIIA 448 (3.2) 281 (2.9) 25 (3.0) 56 (4.7) 36 (5.0) 33 (4.1) 17 (2.4) Po0.001
Stage IIIB 672 (4.8) 477 (4.9) 26 (3.2) 58 (4.8) 42 (5.9) 46 (5.7) 23 (3.3)
Stage IIIC 4576 (32.9) 2384 (24.7) 415 (50.4) 592 (49.3) 350 (49.0) 429 (52.8) 406 (57.4)
Stage III, NOS 2366 (17.0) 2010 (20.8) 62 (7.5) 107 (8.9) 58 (8.1) 73 (9.0) 56 (7.9)
Stage IV 5856 (42.1) 4506 (46.7) 296 (35.9) 389 (32.4) 228 (31.9) 232 (28.5) 205 (29.0)
Grade of disease
Grade 1 580 (4.2) 366 (3.8) 30 (3.6) 47 (3.9) 43 (6.0) 47 (5.8) 47 (6.6) P¼0.005
Grade 2 2443 (17.6) 1684 (17.4) 135 (16.4) 211 (17.6) 123 (17.2) 164 (20.2) 126 (17.8)
Grade 3 8349 (60.0) 5673 (58.7) 531 (64.4) 765 (63.6) 437 (61.2) 490 (60.3) 453 (64.1)
Unknown 2546 (18.3) 1935 (20.0) 128 (15.5) 179 (14.9) 111 (15.5) 112 (13.8) 81 (11.5)
Histology
Serous 9294 (66.8) 6474 (67.0) 553 (67.1) 805 (67.0) 457 (64.0) 532 (65.4) 473 (66.9) Po0.001
Endometrioid 1275 (9.2) 778 (8.1) 78 (9.5) 137 (11.4) 91 (12.7) 100 (12.3) 91 (12.9)
Mucinous 775 (5.6) 554 (5.7) 46 (5.6) 61 (5.1) 36 (5.0) 39 (4.8) 39 (5.5)
Clear cell 394 (2.8) 206 (2.1) 23 (2.8) 62 (5.2) 35 (4.9) 39 (4.8) 29 (4.1)
Others or NOS 2180 (15.7) 1646 (17.0) 124 (15.0) 137 (11.4) 95 (13.3) 103 (12.7) 75 (10.6)
aPercentage of patients for given parameter.
Numbers at risk 
Stage IIIA  448  156 40  7  
Stage IIIB  672  161 44  6  
Stage IIIC 4576 860 149 17
Stage IV  5856 1060 288 53
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Figure 1 Kaplan–Meier analysis based on stage of disease (n¼13918;
Po0.001).
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Figure 2 Kaplan–Meier analysis of patients by extent of lymphadenect-
omy (n¼13918; Po0.001).
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sIn a retrospective review of 127 patients, Carnino et al (1997)
reported that the probability of finding a lymph node metastasis
was significantly higher when more lymph nodes were removed.
These authors suggested that systematic lymphadenectomy should
be performed, rather than lymph node sampling, to determine the
therapeutic impact of lymph node resection in epithelial ovarian
cancers. Determining nodal metastases by palpation at the time of
surgery has been found to have significant limitations (Petru et al,
1994; Arango et al, 2000; Eisenkop and Spirtos, 2001; Tangjitgamol
et al, 2003).
The potential benefit of performing of a systematic lymphade-
nectomy in the primary surgical evaluation of presumed early-
stage ovarian cancer patients has been previously investigated. The
value of systematic retroperitoneal node dissection may be
associated with the upstaging of patients with clinical stage I
cancers, which directs them to further treatment with chemo-
therapy. Furthermore, when initial surgical staging is adequate,
patients with low-risk disease may be spared cytotoxic chemother-
apy (Trimbos et al, 2003; Chan et al, 2007).
The role of systematic lymphadenectomy in advanced stages of
ovarian cancer is somewhat unclear. Some prior studies have
found an association between systematic node dissection and
improved survival. In a retrospective study of 82 patients with
stage III disease, Burghardt et al (1986) showed that pelvic
lymphadenectomy was associated with an improved survival
compared with those patients who did not have a lymphadenect-
omy. In a retrospective review of 150 epithelial cancer patients
based on the Tokai Ovarian Tumor Study Group, Kikkawa et al
(1995) found that the performance of a lymphadenectomy was
associated with improved survival in a multivariate analysis after
controlling for the effects of stage, residual disease, and
histological subtype (Hazard Ratio: 0.677; P¼0.0497).
In a randomised, controlled multi-institutional study of 427
advanced-staged optimally debulked patients, Benedetti Panici
et al (2005) showed a 7-month improvement in disease-free
survival in those who underwent a systematic lymphadenectomy
Table 3 Five-year disease-specific survival based on the extent of lymphadenectomy and clinicopathologic characteristics
No. Total % (s.e.)
0 nodes
% (s.e.)
1 node
% (s.e.)
2–5 nodes
% (s.e.)
6–10 nodes
% (s.e.)
11–20 nodes
% (s.e.)
420 nodes
% (s.e.) Log-rank
Stage of disease Po0.001
Stage III–IV 13918 31.1 (0.5) 26.1 (0.5) 35.2 (2.0) 42.6 (1.8) 48.4 (2.4) 47.5 (2.3) 47.8 (2.8) Po0.001
Stage III 8062 36.7 (0.7) 30.5 (0.8) 37.4 (2.7) 47.7 (2.2) 55.2 (2.9) 51.6 (2.8) 54.5 (3.2) Po0.001
Stage IIIA 448 48.0 (2.8) 40.4 (3.3) 33.9 (12.6) 66.8 (8.4) 61.5 (10.5) 71.4 (9.6) 74.7 (17.5) Po0.001
Stage IIIB 672 42.1 (2.4) 35.1 (2.7) 41.0 (12.9) 55.9 (8.0) 74.0 (7.6) 61.0 (8.8) 81.1 (10.1) P¼0.001
Stage IIIC 4576 36.7 (0.9) 29.0 (1.2) 36.9 (3.1) 45.0 (2.6) 47.8 (3.6) 48.7 (3.3) 51.1 (3.5) Po0.001
Stage IV 5856 24.1 (0.7) 21.4 (0.7) 31.3 (3.1) 33.1 (2.9) 34.6 (4.0) 38.3 (4.1) 32.2 (5.0) Po0.001
Grade of disease Po0.001
Grade 1 580 56.9 (2.4) 49.3 (3.0) 44.5 (11.2) 67.3 (7.7) 71.9 (7.8) 75.2 (7.8) 77.3 (7.6) Po0.001
Grade 2 2443 33.4 (1.2) 28.0 (1.3) 37.3 (5.6) 45.0 (4.3) 59.1 (5.6) 49.4 (5.1) 48.3 (6.1) Po0.001
Grade 3 8349 29.2 (0.6) 24.2 (0.7) 32.6 (2.5) 40.4 (2.3) 44.6 (3.1) 43.5 (2.9) 46.4 (3.6) Po0.001
Histology Po0.001
Serous 9294 30.6 (0.6) 26.1 (0.7) 32.2 (2.5) 41.6 (2.2) 49.7 (3.0) 45.6 (2.9) 44.0 (3.5) Po0.001
Endometrioid 1275 43.6 (1.6) 35.5 (2.0) 53.1 (6.4) 49.8 (5.0) 50.7 (6.7) 63.0 (5.9) 75.4 (5.6) Po0.001
Mucinous 775 33.3 (2.0) 28.1 (2.2) 41.6 (8.5) 48.7 (8.1) 46.1 (10.1) 51.3 (9.6) 47.0 (9.7) Po0.001
Clear cell 394 25.5 (2.9) 18.3 (3.6) 10.1 (9.1) 38.0 (7.0) 39.9 (10.4) 34.4 (9.4) 37.6 (10.3) P¼0.007
s.e.¼standard error.
Table 4 Five-year disease-specific survival analysis for node-positive stage IIIC–IV patients based on the extent of lymphadenectomy and number of
positive nodes
Total number of nodes removed
Positive node
number No. Total % (s.e.)
1 node
% (s.e.)
2–5 nodes
% (s.e.)
6–10 nodes
% (s.e.)
11–20 nodes
% (s.e.)
420 nodes
% (s.e.) Log-rank
All patients 2563 38.0 (1.3) 32.8 (2.6) 36.8 (2.4) 38.7 (3.1) 42.0 (2.9) 41.7 (3.3) P¼0.002
1 positive node 1067 40.1 (1.9) 32.8 (2.6) 45.8 (4.1) 48.1 (6.1) 43.7 (6.5) 58.2 (8.1) Po0.001
2–5 positive nodes 972 37.0 (2.1) — 31.4 (3.0) 38.9 (4.5) 44.2 (4.7) 40.2 (5.7) Po0.001
45 positive nodes 524 35.6 (2.8) — — 29.6 (5.5) 38.7 (4.6) 36.5 (4.6) P¼0.883
s.e.¼standard error.
Table 5 Multivariate analysis
Prognostic
factor
Hazard
ratio
95% confidence
interval P-value
Age at diagnosis
a 1.018 1.016–1.019 Po0.005
Year of diagnosis
b 0.977 0.970–0.984 Po0.005
Stage
c 1.266 1.220–1.315 Po0.005
Grade
d 1.933 1.684–2.219 Po0.005
Histology
e 1.994 1.716–2.316 Po0.005
Extent of
lymphadenectomy
f
0.911 0.861–0.964 P¼0.001
Positive nodes
g 1.338 1.215–1.473 Po0.005
aContinous.
bContinous.
cStage IIIA/B vs IIIC vs IV.
dGrade 1 vs 2–3.
eOthers vs clear
cell.
f0 vs 1 vs 2–5vs 6–10vs X11.
gNo vs yes.
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enlarged lymph nodes. In another randomised trial of 268 patients
with epithelial ovarian cancer macroscopically confined to the
pelvis after cytoreductive surgery, Maggioni et al (2006) compared
the effects of a systematic lymphadenectomy to random sampling
of retroperitoneal lymph nodes. These authors revealed that
systematic lymphadenectomy was associated with an improvement
in both progression-free and overall survival; however, neither was
statistically significant. The investigators stated that this trial
lacked the power to detect a significant difference between the two
groups. These two studies may also have been limited by the short
follow-up duration for assessing long-term survival outcomes
(Benedetti Panici et al, 2005). As such, we performed a large
population-based study to evaluate the potential role of an
extensive lymphadenectomy in women diagnosed with advanced-
stage epithelial ovarian cancer.
In this report of 13918 women with stages III–IV ovarian
cancer, 4260 patients had a dissection of at least one lymph node
performed as part of their initial surgical evaluation. Our data
suggested that a more extensive lymph node dissection was
associated with an improved 5-year disease-specific survival. These
findings were consistent in patients within substages of stage III
disease and those with nodal metastases. Although an increase in
the number of positive nodes was associated with a worsened
survival, the removal of 1, 2–5, 6–10, and 11–20 nodes improved
the outcomes of these patients from 32.8, 36.8, 38.7, 42.0, and
41.7%, respectively. More importantly, multivariate analysis
demonstrated that a more extensive node resection, both as a
categorical and continuous variable, was associated with an
improved survival after adjusting for age, stage, grade, number
of positive nodes, and year of diagnosis (Table 5).
This study is one of the largest series to evaluate the role of
lymphadenectomy in surgically staged advanced ovarian cancer
patients. A large proportion of these patients had an extensive
lymph node resection; in fact, 707 patients had 420 lymph nodes
removed. Given the large size of this cohort, with 13918 patients,
we were able to perform subset analyses on node-positive stage
IIIC and/or IV patients showing consistent results. Similar to the
results of a randomised trial, our data also showed that metastatic
lymph node involvement is associated with poorer survival.
However, in our current separate analysis of over 2563 patients
with stage IIIC disease and nodal metastases, we were able to
perform a detailed subset analysis showing that increasing
numbers of metastatic lymph nodes (1, 2–5, and 45) is associated
with a worsened survival (40.1, 37.0, and 35.6%, respectively).
Our analysis was limited by the lack of information on surgeon’s
subspecialty, volume of residual disease, medical comorbidities,
location of nodal resection (pelvic vs paraaortic), adjuvant
chemotherapy, and treatment of recurrence. In particular, the
extent of extranodal residual disease in stage IIIC and IV patients
and its potential impact on the extent of lymphadenectomy were
not available in the SEER database. Nevertheless, even among
those with stage IIIA disease, defined as microscopic disease in the
upper abdomen, the extent of nodal dissection (6–10, 11–20, and
420 nodes) was associated with an improved survival from 61.5,
71.4, and 74.7%, respectively. Moreover, there was no central
pathology review. Patients who had a less extensive lymphade-
nectomy may have had significant medical and/or surgical
comorbidities, thus, representing patients with poor prognostic
cancers. Furthermore, owing to the retrospective nature of this
analysis, there may exist a selection bias where those patients who
underwent a more extensive lymphadenectomy may have had less
comorbidity, as well as having tumours with more favourable
prognostic features. In addition, the extent of a lymphadenectomy
may not be truly reflected by the reported number of recovered
nodes in our study. Clearly, the extent of the nodal resection by the
surgeon as well as comprehensive processing of the specimens by
the pathologists influences nodal recovery. In addition, a more
thorough lymphadenectomy may be a marker for quality
comprehensive medical and surgical care rather than the
procedure itself resulting in the improved survival of these
patients. Lastly, there are certain patients in whom lymph node
sampling or lymphadenectomy may not be feasible owing to
comorbidity factors, blood loss, or body habitus. In a prospective
randomised trial reported by Benedetti Panici et al (2005) women
who underwent a systematic lymphadenectomy were found to have
more postoperative complications, mostly consisting of lympho-
cytes or lymphoedema. Furthermore, the median operating time
was 90min longer and blood loss was 350ml higher, with 12%
more blood transfusions given when a systematic lymphadenect-
omy was performed.
There are several possible mechanisms that may explain the
improvement in survival that was found to be associated with a
more extensive lymphadenectomy in advanced cancers. A more
complete lymphadenectomy is likely to remove occult microscopic
disease, resulting in a more complete cytoreduction. In the
randomised trial reported by Benedetti Panici et al (2005), patients
with stage IIIB–C and IV epithelial ovarian cancer randomised to
undergo systematic pelvic and paraaortic lymphadenectomy were
found to have a statistically significant increase in positive lymph
nodes compared to those randomised to resection of bulky nodes
only (70 vs 42%; Po0.001). Thus, compared to those who had a
limited lymphadenectomy, 28% more patients in the extensive
lymphadenectomy arm benefited from cytoreduction of occult
nodal metastases. A meta-analysis of the survival effect of
maximum cytoreductive surgery in advanced ovarian carcinoma
reported that each 10% increase in maximum cytoreduction was
associated with a 5.5% increase in median survival time (Bristow
et al, 2002). The magnitude of improved survival reported in our
current study is consistent with these estimates, suggesting that the
improvement in disease-specific survival may be associated with
the removal of additional occult disease.
Furthermore, an extensive lymph node resection may lead to an
improvement in survival by removing micrometastatic disease
within the lymph nodes that may be resistant to chemotherapy.
Prior studies on patients who underwent chemotherapy followed
by second-look surgery showed that 33.3–65.3% of patients with
advanced-stage disease had residual disease in the retroperitoneal
lymph nodes (Burghardt and Winter, 1989; Baiocchi et al, 1998).
These studies suggested that chemotherapy appears to have
minimal effect on tumour deposit in the nodes; thus, retro-
peritoneal lymphadenectomy should be an integral component of
ovarian cancer cytoreductive surgery.
In summary, our retrospective analysis suggests that the extent
of lymphadenectomy is associated with an improvement in
disease-specific survival in patients with advanced ovarian
carcinoma. Furthermore, the extent of nodal disease provides
additional prognostic information. Further trials are warranted to
investigate the treatment of these high-risk patients with nodal
metastases.
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